&w=3840&q=100)
How far is my hospital? In India, it's 15 kms for OPD, 44 kms for admission
Estimates published in The Lancet Regional Health-Southeast Asia journal showed a significant urban-rural disparity – urban older adults availed out-patient facilities within 10 kilometres of reach, while the distance was nearly 30 kilometres for their rural counterparts. read more
Older adults in India are travelling considerable distances to access healthcare, with some commuting up to 15 kilometres for outpatient visits and nearly 44 kilometres for hospitalisation, according to new research.
The study, published in The Lancet Regional Health – Southeast Asia, highlights sharp urban-rural disparities in healthcare access. While seniors in urban areas typically accessed outpatient services within 10 kilometres, their rural counterparts had to travel nearly three times as far, the researchers found.
STORY CONTINUES BELOW THIS AD
The findings are based on data from nearly 32,000 individuals aged 60 and above, surveyed during the first wave of the Longitudinal Ageing Study of India (LASI) in 2017-2018. India's elderly population, currently estimated at 138 million, is projected to rise from 7.4% of the total population in 2001 to 13.2% by 2031.
The study also noted that proximity plays a critical role in healthcare usage: 73% of older adults accessed outpatient services and 40% used inpatient care when facilities were located within 10 kilometres.
However, with an increase in commute distance, a commensurate decline in the use of out-patient services was found – 17 per cent utilisation of facilities for 11-30 kilometres distance, and 10 per cent for 30 kilometres and above, respectively.
A longer commute and far placed facility is a barrier for receiving timely, essential healthcare for people in this age group, often seen grappling with multiple long-term, debilitating conditions requiring continuous care, the team said.
They wrote, 'Older adults, on an average travelled a distance of nine miles (14.54 kilometres) to seek outpatient services and 27 miles (43.62 kilometres) for inpatient care respectively.' State-wise, Tripura, Manipur and Kerala, had the highest in-patient and outpatient visits within 10 kilometres – over 80 per cent, 75 per cent and 59 per cent of older adults availed in-patient services, respectively, while 88 per cent, 78 per cent and 84 per cent availed out-patient ones, respectively
STORY CONTINUES BELOW THIS AD
.The authors attributed Kerala's high rates to 'easy access and better availability of infrastructure'. In Manipur and Tripura, it may be because people rely on nearby facilities during emergency in-patient situations, they said.
Hilly states such as Nagaland, Sikkim and Himachal Pradesh could pose geographical challenges as zero per cent, 17 per cent and about five per cent of older adults in these areas made in-patient visits within 10 kilometres, the study found.
Further, in northeastern states, such as Mizoram and Nagaland, a higher percentage of older adults were found to travel more than 60 kilometres to access in-patient and out-patient services, indicating a poor and limited access to nearby facilities.
Uttar Pradesh, Bihar, and Madhya Pradesh showed a moderate proximity of 11-60 kilometres for older adults accessing out-patient care, but a higher share of in-patient visits at distances beyond 30 kilometres.
The authors added that less variability in commute distance among southern states indicated a well-distributed healthcare infrastructure. For an equitable and inclusive healthcare system in India, improving access to services and reducing geographical barriers are paramount, the team said.
STORY CONTINUES BELOW THIS AD
With inputs from agencies
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
24 minutes ago
- Time of India
This disease might be silently killing millions quietly, says research. Are you at risk?
A recent international study has revealed that millions of people in the US and Europe may be unknowingly living with a dangerous form of fatty liver disease. Published in The Lancet Regional Health Europe, the research indicates that a vast number of individuals are affected by metabolic dysfunction-associated steatotic liver disease (MASLD), with the majority still undiagnosed. Widespread but Largely Undetected The study examined populations in the United States, United Kingdom, Germany, and France, and found that approximately 20 million people across these countries have the more severe variant of MASLD known as metabolic dysfunction-associated steatohepatitis (MASH). Alarmingly, only about 2.5 million have received a formal diagnosis. This means roughly three-quarters of those with the disease—an estimated 16.7 million individuals—remain unaware of their condition. MASLD is the updated term for non-alcoholic fatty liver disease (NAFLD), and it affects people whose liver contains over 5% fat despite little or no alcohol intake. While many patients only develop the earliest and less severe stage known as simple fatty liver, the disease can progress without symptoms and cause serious damage over time. Progressive and Potentially Fatal MASH, the aggressive form of the disease, is associated with inflammation and can lead to fibrosis, or scarring of the liver. If not managed, it may progress to cirrhosis, a stage marked by irreversible liver damage and potential liver failure. The condition is also linked to higher risks of cardiovascular issues, chronic kidney disease, and liver cancer. The study's findings emphasize the urgency of early diagnosis, especially as MASH is particularly common among people with type 2 diabetes and those who are overweight or obese. Researchers noted that around two-thirds of individuals with type 2 diabetes are thought to have MASLD. Urgent Need for Diagnosis and Treatment Dr. Jeffrey Lazarus, the lead author of the study, stressed the economic and health burden posed by undiagnosed MASH. He pointed out that without a significant increase in diagnosis and treatment, the financial costs to healthcare systems could triple over the next two decades. Prof. Emmanouil Tsochatzis of University College London echoed this warning, stating that over 15 million people in the US and Europe are living with the most severe form of fatty liver disease without knowing it. He warned that both human suffering and economic consequences could worsen significantly if diagnosis rates do not improve. Traditionally, MASH has been diagnosed through liver biopsy, but newer, non-invasive tools such as blood tests, ultrasound, and MRI scans have made screening easier. Experts now recommend that individuals with type 2 diabetes, obesity combined with other risk factors, or persistently elevated liver enzymes undergo regular screening. Potential Role of Weight Loss Medications The study has also brought renewed attention to the potential of weight loss medications to help manage MASH. Dr. Paul Brennan, a hepatologist and co-author of the study, highlighted the promise of GLP-1 agonists like Wegovy and Mounjaro. These drugs work by reducing appetite and slowing digestion, leading to weight loss, which in turn may help reduce fat accumulation and scar tissue in the liver. Michael Betel, president of the Fatty Liver Alliance, stressed that individuals with type 2 diabetes or obesity are often not screened for MASH until significant liver damage has occurred. He called for broader liver health assessments and, when appropriate, the use of weight loss drugs as part of a comprehensive treatment strategy. A separate study released around the same time found that the diabetes drug dapagliflozin not only helps reduce blood sugar but also lowers fat and scarring in the liver, suggesting another potential treatment pathway. Risk Factors and Screening According to health authorities like the NHS, those at greater risk of MASLD include people who are overweight, have type 2 diabetes, high blood pressure, high cholesterol, metabolic syndrome, or are over the age of 50. Smoking and thyroid disorders may also increase the risk. Doctors typically begin diagnosis with blood tests that show elevated liver enzymes. If abnormalities are detected, further assessments such as imaging scans or liver elastography (FibroScan) are used to evaluate liver fat and fibrosis levels. With the growing prevalence of MASLD and MASH, the study underscores the critical importance of early screening, timely intervention, and broader public health awareness to address this hidden but escalating health threat.
Time of India
4 days ago
- Time of India
Evidence of CAR T-cell therapy against cancers presented at US conference
New Delhi: Studies have provided evidence of the effectiveness of CAR T-cell therapy against gastric and brain tumours. The papers, presented at the annual meeting of the American Society of Clinical Oncology [ASCO] 2025, held from May 30 to June 3 in Chicago, US, have also been published in journals, including The Lancet and Nature Medicine. Treating cancer using CAR T-cell therapy involves modifying genes in one's T-cells - a type of immune cell - to help fight cancer. In The Lancet paper, that revealed results of phase 2 clinical trials , 156 patients with advanced gastric or gastro-oesophageal junction cancer - and who were resistant to "at least two previous lines of treatment" - were randomly assigned to receive 'satri-cel' or an intervention of physician's choice. Satri-cel, or 'Satricabtagene autoleucel' - a CAR T-cell therapy -- showed "encouraging activity" in phase 1 clinical trials in treating patients with advanced gastric or gastro-oesophageal junction cancer, the team, including researchers from China's Peking University Cancer Hospital and Institute, said. A phase-1 trial primarily looks at establishing a new drug's safety and dose characteristics in about 20-100 healthy volunteers, while a 'phase-2' trial provides evidence of the effectiveness of the experimental drug in about 100-300 volunteers or participants. "In this multicentre, randomised, phase 2 study, satri-cel was associated with a statistically significant increase in progression-free survival and clinically meaningful increase in overall survival compared with TPC (treatment of physician's choice), along with a manageable safety profile in patients," the authors wrote. They added that it is the "first randomised controlled study of a CAR T-cell therapy in solid tumours". In the second study, published in the Nature Medicine journal, researchers from the University of Pennsylvania, US, said that CAR T-cell therapy "shows promise for slowing tumour growth in a notoriously aggressive and fast-growing brain cancer ". The phase-1 trial involved 18 patients with glioblastoma who received the treatment. "Tumour regression (becoming smaller) occurred in eight of 13 patients (62 per cent) with measurable disease," the authors wrote. In March, a CAR T-cell therapy, indigenously developed by researchers from the Indian Institute of Technology-Bombay and Tata Memorial Hospital, Mumbai, showed a 73 per cent response rate in patients of leukaemia and lymphoma, who either relapsed following a period of remission or were resistant to treatment. The results of the phase 1 and 2 clinical trials are published in The Lancet Haematology journal. PTI
The Hindu
4 days ago
- The Hindu
Evidence of CAR T-cell therapy against cancers presented at US conference
Studies have provided evidence of the effectiveness of CAR T-cell therapy against gastric and brain tumours. The papers, presented at the annual meeting of the American Society of Clinical Oncology (ASCO) 2025, held from May 30 to June 3 in Chicago, US, have also been published in journals, including The Lancet and Nature Medicine. Treating cancer using CAR T-cell therapy involves modifying genes in one's T-cells – a type of immune cell – to help fight cancer. In The Lancet paper, that revealed results of phase 2 clinical trials, 156 patients with advanced gastric or gastro-oesophageal junction cancer – and who were resistant to 'at least two previous lines of treatment' – were randomly assigned to receive 'satri-cel' or an intervention of physician's choice. Satri-cel, or 'Satricabtagene autoleucel' – a CAR T-cell therapy -- showed 'encouraging activity' in phase 1 clinical trials in treating patients with advanced gastric or gastro-oesophageal junction cancer, the team, including researchers from China's Peking University Cancer Hospital and Institute, said. A phase-1 trial primarily looks at establishing a new drug's safety and dose characteristics in about 20-100 healthy volunteers, while a 'phase-2' trial provides evidence of the effectiveness of the experimental drug in about 100-300 volunteers or participants. 'In this multicentre, randomised, phase 2 study, satri-cel was associated with a statistically significant increase in progression-free survival and clinically meaningful increase in overall survival compared with TPC (treatment of physician's choice), along with a manageable safety profile in patients,' the authors wrote. They added that it is the 'first randomised controlled study of a CAR T-cell therapy in solid tumours'. In the second study, published in the Nature Medicine journal, researchers from the University of Pennsylvania, US, said that CAR T-cell therapy 'shows promise for slowing tumour growth in a notoriously aggressive and fast-growing brain cancer'. The phase-1 trial involved 18 patients with glioblastoma who received the treatment. 'Tumour regression (becoming smaller) occurred in eight of 13 patients (62 per cent) with measurable disease,' the authors wrote. In March, a CAR T-cell therapy, indigenously developed by researchers from the Indian Institute of Technology-Bombay and Tata Memorial Hospital, Mumbai, showed a 73 per cent response rate in patients of leukaemia and lymphoma, who either relapsed following a period of remission or were resistant to treatment. The results of the phase 1 and 2 clinical trials are published in The Lancet Haematology journal.
